---
title: "CLRB: Net loss increased as R&D ramped up, with cash at $34M and significant funding needs ahead"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295788898.md"
description: "Net loss widened to $6.9M in Q2 2026 as R&D spending surged for new clinical trials, while cash reserves stood at $34M. The company faces substantial going concern risks and will require additional capital to advance its lead cancer drug candidate through regulatory approval and commercialization.Original document: Cellectar Biosciences, Inc. [CLRB] SEC 10-Q Quarterly Report — Aug. 13 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T11:18:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295788898.md)
  - [en](https://longbridge.com/en/news/295788898.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295788898.md)
generator: "portal-rs"
---

# CLRB: Net loss increased as R&D ramped up, with cash at $34M and significant funding needs ahead

Net loss widened to $6.9M in Q2 2026 as R&D spending surged for new clinical trials, while cash reserves stood at $34M. The company faces substantial going concern risks and will require additional capital to advance its lead cancer drug candidate through regulatory approval and commercialization.

Original document: Cellectar Biosciences, Inc. \[CLRB\] SEC 10-Q Quarterly Report — Aug. 13 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CLRB.US](https://longbridge.com/en/quote/CLRB.US.md)

## Related News & Research

- [CLRB: Lead radioconjugate shows strong efficacy in WM, with broad pipeline and solid financials](https://longbridge.com/en/news/296262059.md)
- [CLRB: Strong clinical progress and financing position support upcoming NDA submission in WM](https://longbridge.com/en/news/295790594.md)
- [One chart shows a big warning sign for the future of AI](https://longbridge.com/en/news/296329028.md)
- [Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/296502875.md)
- [AI isn’t close to curing cancer. This startup says it knows what it will take.](https://longbridge.com/en/news/296352961.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**